2016-06-06
Proteo receives US$ 1 million grant for a new Elafin drug formulation
2015-03-12
Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs
2014-12-05
Proteo Biotech AG expands Management Board
2014-11-21
Final Analysis of the Phase II Clinical Study on Elafin in coronary artery bypass surgery completed
2014-05-20
$ 4.8 Million Funding for Proteo's Advanced Orphan Drug Development
2013-11-08
Patient recruitment and treatment in Elafin CABG Phase II clinical trial completed
2013-03-20
FDA grants Orphan Drug Designation to Elafin for prevention of inflammatory complications of transthoracic esophagectomy
2013-01-10
FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension
2012-12-11
Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)
2012-06-27
Further rationale for Elafin treatment in newborn infants – convincing preclinical evidence in a neonatal pulmonary model
